China NMPA Inspection - Pingyu Bingwang Biotechnology Co., Ltd. - July 28, 2017

On July 28, 2017, the Henan Provincial Food and Drug Administration, operating under the broader regulatory framework of China's National Medical Products Administration (NMPA), published a 'Notice of Supervision and Inspection' concerning Pingyu Bingwang Biotechnology Co., Ltd. This official notification indicates that a regulatory oversight activity, focused on supervision and inspection, was conducted involving the company. While the notice confirms the occurrence of such an event, the provided text does not specify the precise dates on which the inspection itself took place. Furthermore, the document is limited to announcing the notice and does not disclose any substantive details regarding the inspection's findings. Consequently, information pertaining to any main violations, identified issues, or areas of non-compliance discovered during the inspection is absent. Additionally, the notice does not outline any specific required actions or corrective measures that Pingyu Bingwang Biotechnology Co., Ltd. might need to undertake in response to the regulatory review. The notice serves primarily to formally record the supervisory event without detailing its outcomes.